Generic imatinib vs Glivec for newly diagnosed CML
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether a generic version of imatinib (Carcemia®) works as well and is as safe as Glivec® in real-life care for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). It may help confirm that the generic option is effective for controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You were newly diagnosed with Philadelphia chromosome–positive (Ph+) CML in the chronic phase
- Your diagnosis must be confirmed within 3 months before enrolling
- Your liver blood tests (aminotransferases and bilirubin) must be no more than 2 times the normal upper limit
- Your kidney blood test (creatinine) must be no more than 1.5 times the normal upper limit
- You must be able to sign a consent form to join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This study compares two targeted pills—flumatinib and imatinib—in people newly diagnosed with chronic-phase CML (a blood cancer). It aims to see which one works better and is safer soon after diagnosis.
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.